Astellas Pharma Europe Ltd-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Astellas Pharma Europe Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8011784
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月13日
◆ページ数:19
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:イギリス
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥26,750見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥53,500見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥80,250見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Astellas Pharma Europe Ltd (Astellas Pharma), a subsidiary of Astellas Pharma Inc is a manufacturer and distributor of drug products. The company provides pharmaceutical drugs in the areas of oncology, transplantation, urology, anti-infective, pain management and dermatology. It also provides discovery and development of new medicines and produce wide range of established products. Astellas Pharma conducts research and development of drug products. The company operates through its drug discovery research center in Japan. It operates in Iceland, Ireland, South Africa, Portugal, Spain, Norway, Denmark, Belgium, the Netherlands, Germany, Switzerland, Hungary, Serbia, Italy, Turkey, France, Romania, Ukraine, Russia, the UAE and the UK, among others. Astellas Pharma is headquartered in Chertsey, the UK.

Astellas Pharma Europe Ltd – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Astellas Pharma Europe Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Astellas Pharma Europe Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Astellas Pharma Europe Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Astellas Pharma Europe Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Astellas Pharma Europe Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
Astellas Pharma Europe Ltd, Pharmaceuticals & Healthcare, Deal Details 10
Asset Purchase 10
MediGene Completes Sale Of European Rights For Eligard To Astellas 10
Licensing Agreements 12
Optimer Pharma Enters Into Licensing Agreement With Astellas Pharma Europe For Fidaxomicin 12
Astellas Pharma Europe Expands Its Licensing Agreement With TOLMAR For Eligard 14
Asset Transactions 15
Grunenthal to Acquire Qutenza from Astellas Pharma Europe 15
Astellas Pharma Europe Ltd – Key Competitors 16
Astellas Pharma Europe Ltd – Key Employees 17
Astellas Pharma Europe Ltd – Locations And Subsidiaries 18
Head Office 18
Other Locations & Subsidiaries 18
Appendix 19
Methodology 19
About GlobalData 19
Contact Us 19
Disclaimer 19

List of Tables
Astellas Pharma Europe Ltd, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Astellas Pharma Europe Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Astellas Pharma Europe Ltd, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Astellas Pharma Europe Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Astellas Pharma Europe Ltd, Deals By Therapy Area, 2011 to YTD 2017 8
Astellas Pharma Europe Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
MediGene Completes Sale Of European Rights For Eligard To Astellas 10
Optimer Pharma Enters Into Licensing Agreement With Astellas Pharma Europe For Fidaxomicin 12
Astellas Pharma Europe Expands Its Licensing Agreement With TOLMAR For Eligard 14
Grunenthal to Acquire Qutenza from Astellas Pharma Europe 15
Astellas Pharma Europe Ltd, Key Competitors 16
Astellas Pharma Europe Ltd, Key Employees 17
Astellas Pharma Europe Ltd, Subsidiaries 18

★海外企業調査レポート[Astellas Pharma Europe Ltd-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Trilogy Energy Corp. (TET):企業の財務及び戦略的SWOT分析
    Summary Trilogy Energy Corp. (TET) is a petroleum and natural gas producer that acquires, develops, produces and sells natural gas, crude oil and natural gas liquids. The company owns and operates oil and gas properties in Alberta. The company was formed as an income trust and as a result of a spino …
  • CIGNA Corporation:企業の戦略・SWOT・財務分析
    SummaryCIGNA Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360˚ view of the company. Key Findi …
  • Asgent, Inc. (4288):企業財務及び戦略的SWOT分析
    Summary Asgent, Inc. (Asgent) is a technology company that develops and distributes network security solutions for enterprise and medium sized organizations. The company offers security products. It provides services such as managed security services, security assessment, security product sales and …
  • Cleveland BioLabs Inc (CBLI):企業の財務・戦略的SWOT分析
    Summary Cleveland BioLabs Inc (Cleveland) is a biopharmaceutical company that develops and commercializes drugs to treat cancer, orphan indications and protect healthy tissues from radiation and chemotherapy. The company’s product includes entolimod, a recombinant protein that acts as an agonist of …
  • China General Plastics Corp (1305):企業の財務及び戦略的SWOT分析
    Summary China General Plastics Corporation (CGPC) a subsidiary of USI Group is a chemical company that manufactures PVC resin. The company manufactures poly vinyl chloride resin and vinyl films. Its products include raw materials, construction products, film and sheet products, leather products, and …
  • Warba Insurance Company – K.S.C.P (WINS):企業概要・SWOT分析
    This report is a crucial resource for industry executives and anyone looking to access key information about "Warba Insurance Company - K.S.C.P" The report utilizes a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessible format. Timetric …
  • City Lodge Hotels Limited:企業の戦略・SWOT・財務分析
    City Lodge Hotels Limited - Strategy, SWOT and Corporate Finance Report Summary City Lodge Hotels Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • XOMA Corp (XOMA):製薬・医療:M&Aディール及び事業提携情報
    Summary XOMA Corp (Xoma), formerly Xoma Ltd, is a biopharmaceutical company that develops antibody-based therapeutics. Its lead product, gevokizumab is a monoclonal antibody used for the treatment of a wide variety of inflammatory diseases and other diseases. Its other pipeline products include X358 …
  • ClearCount Medical Solutions, Inc.:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' ClearCount Medical Solutions, I …
  • Gentag Inc:医療機器:M&Aディール及び事業提携情報
    Summary Gentag Inc (Gentag) is a medical device company that patent and develops wireless sensor technology products. The company provides wireless products to diagnostics and personal health. It offers wireless sensor network services. Gentag’s products comprise medication and packaging sensor, dia …
  • AdCare Health Systems Inc (ADK):企業のM&A・提携動向(医療分野)
    Summary AdCare Health Systems Inc (AdCare) is a healthcare real estate investment company that offers real estate investment services. The company invests primarily in real estate purposed for senior living and long-term healthcare through facility lease, and sub-lease transactions. It offers long-t …
  • JDA Software Group, Inc.:企業の戦略的SWOT分析
    JDA Software Group, Inc. - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Human Longevity Inc-製薬・医療分野:企業M&A・提携分析
    Summary Human Longevity Inc (HLI) is a genomics-based, technology-driven company which develops database of whole genome, phenotype and clinical data. Its discovery capabilities include streamlining drug development, rescuing and repurposing drugs from failed clinical trials and discovery of biomark …
  • Elecnor SA (ENO):企業のM&A・提携動向(発電分野)
    Summary Elecnor SA (Elecnor) is an alternative energy company that offers energy services. The company offers development infrastructure, renewable energies and concessions, and investment businesses. It specializes in engineering, construction, start-up, supply, installation and assembly, operation …
  • BioChain Institute Inc-医療機器分野:企業M&A・提携分析
    Summary BioChain Institute Inc (BioChain) is a medical device company that designs, develops and markets diagnostic products. The company provides processed bio-sample products and analysis services used in translational medicine, companion diagnostics, and clinical product research and development. …
  • Logicalis Group Limited:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Logicalis Group Limited Mergers …
  • Geodynamics Limited (GDY):企業のM&A・提携動向(発電分野)
    Summary Geodynamics Limited (Geodynamics) is a geothermal company that offers exploration and development services. The company develops zero emissions renewable energy generation from enhanced geothermal systems. It provides services in drilling deep, high temperature, high pressure wells in granit …
  • Hitachi High-Technologies Corporation (8036):企業概要、財務及び戦略的SWOT分析
    Summary Hitachi High-Technologies Corporation (Hitachi High-Tech) is a technology product company. The company manufactures various products for information technology and other industries. Its products include semiconductor device manufacturing equipment, evaluation, and analysis equipment; analyze …
  • Finolex Industries Limited (FINPIPE):企業の財務及び戦略的SWOT分析
    Summary Finolex Industries Limited (FIL) is a pipe manufacturing company that manufactures and markets PVC pipes and PVC resins. The company offers products that include selfit PVC-U pipes, ringfit PVC-U pipes, PVC-U column pipes, moulded fittings, fabricated fittings, protector well casings and scr …
  • MMC Contrarian Limited:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' MMC Contrarian Limited Mergers …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆